Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

Hepatology

Volumn 36, Issue 2, 2002, Pages 464-473

  Yang, Huiling ^a   Westland, Christopher E ^a   Delaney, William E ^a   Heathcote, Elizabeth J ^b   Ho, Victoria ^a   Fry, John ^a   Brosgart, Carol ^a   Gibbs, Craig S ^a   Miller, Michael D ^a   Xiong, Shelly ^a  

^a GILEAD SCIENCES   (United States)

^b TORONTO WESTERN HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; FAMCICLOVIR; LAMIVUDINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE;

ADULT; AMINO ACID SUBSTITUTION; ANTIMICROBIAL THERAPY; ANTIVIRAL ACTIVITY; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; DNA SEQUENCE; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MALE; MUTATION; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SEQUENCE ANALYSIS; UNINDEXED SEQUENCE; VIRUS ISOLATION; VIRUS LOAD;

EID: 18444383362     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.34740     Document Type: Article

References (51)

1. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis
2. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B
3. A preliminary trial of lamivudine for chronic hepatitis B infection
4. Lamivudine is effective in suppressing hepatitis B virus DNA in Chinese hepatitis B surface antigen carriers: A placebo-controlled trial
5. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy
6. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years
7. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B
8. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy
9. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis b virus after long-term lamivudine therapy
10. Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation
11. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
12. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea
13. Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B
14. Sensitivity of L-(-)2,3-dideoxythiacytidine resistant hepatitis B virus to other antiviral nucleoside analogues
15. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance
16. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (-)-β-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-β-L-arabinofuranosyluracil
17. Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and retakeover by wild type after cessation of therapy
18. Resistance of hepatitis B virus to antiviral drugs: Current aspects and directions for future investigation
19. A novel selective broad-spectrum anti-DNA virus agent
20. Inhibitory effect of 9-(2-phosphonylmethoxyethyl)-adenine (PMEA) on human and duck hepatitis B virus infection
21. Inhibition of duck hepatitis B virus replication by 9-(2-phosphonyl-methoxyethyl)adenine, an acyclic phosphonate nucleoside analogue
22. Increased hepatocyte turnover and inhibition of woodchuck hepatitis B virus replication by adefovir in vitro do not lead to reduction of the closed circular DNA
23. Antiviral efficacy and pharmacokinetics of oral adefovir dipivoxil in chronically woodchuck hepatitis virus-infected woodchucks
24. A placebo-controlled phase I/II study of adefovir dipivoxil in patients with chronic hepatitis B virus infection
25. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants
26. Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: Durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin
27. Safety and efficacy of adefovir dipivoxil in patients coinfected with HIV-1 and lamivudine-resistant hepatitis B virus: An open-label pilot study
28. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
29. In vitro evaluation of hepatitis B virus polymerase mutations associated with famciclovir resistance
30. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro
31. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus
32. Analysis and cloning of eukaryotic genomic DNA
33. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure
34. Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B
35. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B: Hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss
36. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient
37. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation
38. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC)
39. Novel mutation (K70E) in human immunodeficiency virus type 1 reverse transcriptase confers decreased susceptibility to 9-[2-(phosphonomethoxy)ethoxy)ethyl]adenine in vitro
40. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from AIDS patients after prolonged adefovir dipivoxil therapy
41. Adefovir and tenofovir susceptibilities of HIV-1 after 24 to 48 weeks of adefovir dipivoxil therapy: Genotypic and phenotypic analyses of study GS-96-408
42. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: A randomized controlled trial
43. Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)
44. Phenotypic mechanism of HIV-1 resistance to 3′-azido-3′-deoxythymidine (AZT): Increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase
45. A mechanism of AZT resistance: An increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase
46. Differential removal of thymidine nucleotide analogues from blocked DNA chains by human immunodeficiency virus reverse transcriptase in the presence of physiological concentrations of 2′-deoxynucleoside triphosphates
47. Efficient pyrophosphorolysis by a hepatitis B virus polymerase may be a primer-unblocking mechanism
48. Increased drug susceptibility of HIV-1 reverse transcriptase mutants containing M184V and zidovudine-associated mutations: Analysis of enzyme processivity, chain-terminator removal and viral replication
49. Alterations in intrahepatic expression of duck hepatitis B viral markers with ganciclovir chemotherapy
50. Demonstration of duck hepatitis B virus in bile duct epithelial cells: Implications for pathogenesis and persistent infection
51. Characterization of novel human hepatoma cell lines with stable Hepatitis b virus secretion for evaluating new compounds against Lamivudine- and Penciclovir-resistant virus